Latest Adherium (ASX:ADR) News

Adherium Limited has successfully closed the institutional portion of its entitlement offer, increasing the raise to $4.492 million due to robust demand. The company now invites retail shareholders to participate as it advances its digital respiratory health solutions.

Adherium Limited has announced an accelerated non-renounceable entitlement offer to raise approximately A$4 million, issuing new shares and options to fund expansion and product development. The offer includes a Top-Up Facility and is partially underwritten, signaling a strategic push to scale its respiratory monitoring technology.

Adherium Limited is raising up to $4 million through a partially underwritten entitlement offer to expand its US digital health platform and recruit key personnel. The capital raise supports scaling patient onboarding and advancing its FDA-cleared smart inhaler technology.

Adherium Limited has locked in $900,000 through convertible notes to fund the expansion of its Hailie® Smartinhaler® platform in the US, pending shareholder approval at the upcoming AGM.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Adherium reports strong patient adoption and new US partnerships, positioning for significant expansion in 2025 with a target of 9,000 active users and entry into the Pharmacy Benefit Management sector.